Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Shuxin Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9525-6142; OpenAlex author ID A5103052956. Sources: OpenAlex.

Their work

Papers
16 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2019: 2 papers · 2020: 6 papers · 2021: 5 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 16

  1. Integrin β6-Targeted CAR-T Cells exhibit potent antitumor activity in β6-Positive pancreatic ductal adenocarcinoma and lung adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-25-1246↗
  2. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer [Cancer Lett. 502 (2021) 9-24]. Co-author DOI 10.1016/j.canlet.2024.216697↗
  3. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer. Co-author DOI 10.1186/s13046-023-02854-3↗
  4. LINC00460 promotes pancreatic cancer progression by sponging miR-491-5p. First author DOI 10.1002/jgm.3333↗
  5. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.12.018↗
  6. The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer. First author DOI 10.1080/2162402x.2021.1897295↗
  7. Identification of Circulating Biomarkers and Construction of a Prognostic Signature for Survival Prediction in Locally Advanced Pancreatic Cancer After Irrever… First author DOI 10.2147/jir.s307884↗
  8. Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer. First author DOI 10.2147/jir.s331023↗
  9. Oxidative stress induces monocyte-to-myofibroblast transdifferentiation through p38 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.41↗
  10. Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbrc.2020.02.042↗
  11. Score for the Overall Survival Probability of Patients With Pancreatic Adenocarcinoma of the Body and Tail After Surgery: A Novel Nomogram-Based Risk Assessmen… First author DOI 10.3389/fonc.2020.00590↗
  12. SYPL1 Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma via Suppression of ROS-Induced ERK Activation. Co-author DOI 10.3389/fonc.2020.01482↗
  13. A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection. First author DOI 10.3389/fonc.2020.01564↗
  14. Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer. First author DOI 10.3389/fonc.2020.622318↗
  15. Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer. Co-author DOI 10.1155/2019/9346017↗
  16. Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity sco… Co-author DOI 10.1186/s12885-019-5607-3↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shengping Li · 14 shared papers, 2019–2024 · strength 1.94
  2. Chaobin He · 13 shared papers, 2019–2024 · strength 1.81
  3. Xin Huang · 6 shared papers, 2020–2024 · strength 0.74
  4. Fengxiao Xie · 4 shared papers, 2020–2024 · strength 0.56
  5. Xiaojun Lin · 4 shared papers, 2019–2020 · strength 0.53
  6. Jun Wang · 3 shared papers, 2020–2024 · strength 0.39
  7. Yunda Song · 3 shared papers, 2020–2021 · strength 0.34
  8. Yize Mao · 3 shared papers, 2020 · strength 0.31
  9. Guangmei Yan · 2 shared papers, 2021–2024 · strength 0.29
  10. Jing Cai · 2 shared papers, 2021–2024 · strength 0.29
  11. Peng Li · 1 shared paper, 2026 · strength 0.23
  12. Lingchao Shi · 1 shared paper, 2026 · strength 0.23
  13. Zhiqiang Fu · 1 shared paper, 2023 · strength 0.16
  14. Yu Zhou · 1 shared paper, 2023 · strength 0.16
  15. Chonghui Hu · 1 shared paper, 2023 · strength 0.16
  16. Rufu Chen · 1 shared paper, 2023 · strength 0.16
  17. Yuming Luo · 1 shared paper, 2023 · strength 0.16
  18. Renpeng Xia · 1 shared paper, 2023 · strength 0.16
  19. Shangyou Zheng · 1 shared paper, 2023 · strength 0.16
  20. Rihua He · 1 shared paper, 2023 · strength 0.16
  21. Wuguo Deng · 1 shared paper, 2021 · strength 0.13
  22. Jiali Wu · 1 shared paper, 2021 · strength 0.13
  23. Peng Huang · 1 shared paper, 2020 · strength 0.11
  24. Xiang‐Ming Lao · 1 shared paper, 2019 · strength 0.10
  25. Bokang Cui · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.